Product Highlight - Oncaspar

ONCASPAR^©: A FOUNDATION OF STRENGTH THROUGHOUT

• Indicated in HK, EU & USA as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL) in paediatric patients from birth to 18 years, and adult patients. ^1,2
• Demonstrated high therapeutic efficacy in wide range of clinical trials for newly diagnosed/relapsed ALL patients ²
• Potentially reduces immunogenicity: Patients using ONCASPAR^© develop fewer anti-asparaginase antibodies compared to native E. coli asparaginase ²
• Convenient dosing schedule & increased cost-effectiveness: ONCASPAR^© offers less frequent 2 weeks dosing compared with other asparaginases (1 dose vs up to 6 doses) ^1,3
• Lyophilised formulation with an extended shelf-life of 36 months ¹

References:
1. Oncaspar Summary of Product Characteristics, Servier HK.
2. Heo YA, Syed YY, Keam SJ. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia. Drugs. 2019 May;79(7):767-777. doi: 10.1007/s40265-019-01120-1.
3. Hu X, Wildman KP, Basu S, Lin PL, Rowntree C, Saha V. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Econ Rev. 2019 Dec 29;9(1):40. doi: 10.1186/s13561-019-0257-3.